Specify a stock or a cryptocurrency in the search bar to get a summary
CSL Ltd
CSLCSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia. Address: 655 Elizabeth Street, Melbourne, VIC, Australia, 3000
Analytics
WallStreet Target Price
490.78 AUDP/E ratio
37.3879Dividend Yield
1.32 %Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures CSL
Dividend Analytics CSL
Dividend growth over 5 years
59 %Continuous growth
2 yearsPayout Ratio 5 years average
59 %Dividend History CSL
Stock Valuation CSL
Financials CSL
Results | 2019 | Dynamics |